循证引颈变革，埃万妥单抗聚合调养界说EGFR突变NSCLC一线新程序

埃万妥单抗聚合调养有筹算为不同EGFR突变晚期NSCLC东说念主群提供精确调养选拔。

*以下践诺仅供医疗卫生专科东说念主士浏览。

参考文件：

[1] 中华医学会学分会. 中华医学会肺癌临床诊疗指南（2025版）[J]. 中华肿瘤杂志, 2025, 47(9): 769-810.

[2] Boustany Y, et al. Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa. Cancer Control. 2022;29: 1-9.

[3] Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.

[4] Zhou C. et al. Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis. 2023 ESMO Asia.513MO.

[5]Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24;391(16):1486-1498.

[6]Yang JC, et al. MARIPOSA Investigators. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.

[7]Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.

审批编码：CP-558517

批准分发日历：12/16/2025

灵验期：12/16/2026

*“医学界”痛苦所发表践诺专科、可靠，但不合践诺的准确性作念出情愿；请相关各方在禁受或以此行为决策依据时另行核查。